Search Results

You are looking at 21 - 30 of 294 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations

Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns

approvals in TNBC. The first study to demonstrate potential benefit of the addition of a PD-1 inhibitor to neoadjuvant chemotherapy was the iSPY2 study, in which the pCR rate almost tripled from 22% to 60%. 10 In this study, pembrolizumab was added only to

Full access

SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven

curative cohorts. Another limitation is that information about treatment intent is not included in the NCR because it includes only the treatments patients actually received. For example, patients who intended to receive a neoadjuvant chemotherapy and

Full access

The Integration of Chemotherapy and Surgery for Bladder Cancer

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

study . J Urol 1995 ; 153 : 964 – 973 . 15 Shipley WU Winter KA Kaufman DS . Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and

Full access

Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series

Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao

’ tumor-agnostic ctDNA analyses. 23 In light of the MSI-H subset data from KEYNOTE-062, 3 we added pembrolizumab to neoadjuvant chemotherapy extrapolating from the high response rates observed for this subgroup with combination chemotherapy and

Full access

Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study

Willemieke P.M. Dijksterhuis, Anouk E.J. Latenstein, Jessy Joy van Kleef, Rob H.A. Verhoeven, Jeanne H.M. de Vries, Marije Slingerland, Elles Steenhagen, Joos Heisterkamp, Liesbeth M. Timmermans, Marian A.E. de van der Schueren, Martijn G.H. van Oijen, Sandra Beijer, and Hanneke W.M. van Laarhoven

because data on skeletal muscle mass and strength were unavailable. Treatment Analyses were stratified according to treatment type: (1) neoadjuvant chemoradiotherapy (nCRT) followed by a surgical resection, (2) neoadjuvant chemotherapy (nCT) followed by a

Full access

Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

,364), and neoadjuvant chemotherapy (n=205). This analysis is inclusive of data from September 2005 to September 2013. The clinicopathologic characteristics were analyzed and compared using chi-square test for categorical variables and the Kruskal

Full access

New Issues in Systemic Therapy for Ovarian Cancer

Deborah K. Armstrong

surgery first.” Neoadjuvant Chemotherapy For patients who are not good candidates for surgery, neoadjuvant chemotherapy is an option. In a 2010 non-inferiority study, neoadjuvant chemotherapy followed by interval debulking surgery was not inferior

Full access

Evolving Treatment Paradigm in the Treatment of Locally Advanced Rectal Cancer

Clayton A. Smith and Lisa A. Kachnic

patients with clinical T4 disease, involved CRM, or locally unresectable/medically inoperable tumors, long-course chemoRT with or without more intensive neoadjuvant chemotherapy is recommended given the available data for pathologic downstaging with

Full access

Ovarian Cancer, Version 3.2012

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

greater than 50 units/mL (instead of a CA-125 level >200 units/mL) is a better discriminator of cancer versus benign masses for premenopausal women. 16 Primary Treatment Using Neoadjuvant Chemotherapy The NCCN Ovarian Cancer Panel recommends up

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

surgical candidate, optimal cytoreduction (residual disease <1 cm [R1] and preferably removal of macroscopic disease [R0]) appears feasible, and fertility is not a concern. Neoadjuvant chemotherapy (NACT) with interval debulking surgery (IDS) should be